Apixaban (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Apixaban" in Italian language version.

refsWebsite

Global rank Italian rank

7doi.org

2^nd place

7^th place

6nih.gov

4^th place

9^th place

6oadoi.org

799^th place

22^nd place

1archive.org

6^th place

8^th place

1theheart.org

low place

1clinicaltrials.gov

5,225^th place

5,296^th place

1cardiobrief.org

low place

1pharmastar.it

low place

7,927^th place

1agenziafarmaco.gov.it

low place

1,603^rd place

agenziafarmaco.gov.it

AIFA, Comunicazione relativa ai nuovi anticoagulanti orali Eliquis®, Pradaxa®, Xarelto® Importante informativa sui fattori di rischio di sanguinamento – (PDF), su agenziafarmaco.gov.it, Agenzia Italiana del farmaco, 11 settembre 2013. URL consultato il 30 settembre 2013.

archive.org

AG. Turpie, Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases., in Arterioscler Thromb Vasc Biol, vol. 27, n. 6, giugno 2007, pp. 1238-47, DOI:10.1161/ATVBAHA.107.139402, PMID 17379841.

cardiobrief.org

Husten L, ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study, su CardioBrief, WordPress.com, 22 giugno 2011. URL consultato il 23 giugno 2011.

clinicaltrials.gov

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE), su NCT00412984, ClinicalTrials.gov. URL consultato il 23 giugno 2011.

doi.org

dx.doi.org

AG. Turpie, Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases., in Arterioscler Thromb Vasc Biol, vol. 27, n. 6, giugno 2007, pp. 1238-47, DOI:10.1161/ATVBAHA.107.139402, PMID 17379841.
SJ. Connolly, J. Eikelboom; C. Joyner; HC. Diener; R. Hart; S. Golitsyn; G. Flaker; A. Avezum; SH. Hohnloser; R. Diaz; M. Talajic, Apixaban in patients with atrial fibrillation., in N Engl J Med, vol. 364, n. 9, marzo 2011, pp. 806-17, DOI:10.1056/NEJMoa1007432, PMID 21309657.
MR. Lassen, BL. Davidson; A. Gallus; G. Pineo; J. Ansell; D. Deitchman, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement., in J Thromb Haemost, vol. 5, n. 12, dicembre 2007, pp. 2368-75, DOI:10.1111/j.1538-7836.2007.02764.x, PMID 17868430.
MR. Lassen, A. Gallus; GE. Raskob; G. Pineo; D. Chen; LM. Ramirez; MR. Lassen; A. Gallus; G. Pineo; G. Raskob; J. Ansell, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement., in N Engl J Med, vol. 363, n. 26, dicembre 2010, pp. 2487-98, DOI:10.1056/NEJMoa1006885, PMID 21175312.
JH. Alexander, RD. Lopes; S. James; R. Kilaru; Y. He; P. Mohan; DL. Bhatt; S. Goodman; FW. Verheugt; M. Flather; K. Huber, Apixaban with antiplatelet therapy after acute coronary syndrome., in N Engl J Med, vol. 365, n. 8, agosto 2011, pp. 699-708, DOI:10.1056/NEJMoa1105819, PMID 21780946.
Christopher B. Granger, John H. Alexander, John J.V. McMurray, Renato D. Lopes, Elaine M. Hylek, Michael Hanna, Apixaban versus Warfarin in Patients with Atrial Fibrillation, in New England Journal of Medicine, vol. 365, n. 11, 2011, pp. 981–992, DOI:10.1056/NEJMoa1107039. URL consultato il 27 gennaio 2013.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical Cost Reductions Associated with the Usage of Novel Oral Anticoagulants vs. Warfarin Among Atrial Fibrillation Patients, Based on the RE-LY, ROCKET-AF and ARISTOTLE Trials., in J Med Econ, marzo 2012, DOI:10.3111/13696998.2012.680555, PMID 22449118.

nih.gov

ncbi.nlm.nih.gov

AG. Turpie, Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases., in Arterioscler Thromb Vasc Biol, vol. 27, n. 6, giugno 2007, pp. 1238-47, DOI:10.1161/ATVBAHA.107.139402, PMID 17379841.
SJ. Connolly, J. Eikelboom; C. Joyner; HC. Diener; R. Hart; S. Golitsyn; G. Flaker; A. Avezum; SH. Hohnloser; R. Diaz; M. Talajic, Apixaban in patients with atrial fibrillation., in N Engl J Med, vol. 364, n. 9, marzo 2011, pp. 806-17, DOI:10.1056/NEJMoa1007432, PMID 21309657.
MR. Lassen, BL. Davidson; A. Gallus; G. Pineo; J. Ansell; D. Deitchman, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement., in J Thromb Haemost, vol. 5, n. 12, dicembre 2007, pp. 2368-75, DOI:10.1111/j.1538-7836.2007.02764.x, PMID 17868430.
MR. Lassen, A. Gallus; GE. Raskob; G. Pineo; D. Chen; LM. Ramirez; MR. Lassen; A. Gallus; G. Pineo; G. Raskob; J. Ansell, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement., in N Engl J Med, vol. 363, n. 26, dicembre 2010, pp. 2487-98, DOI:10.1056/NEJMoa1006885, PMID 21175312.
JH. Alexander, RD. Lopes; S. James; R. Kilaru; Y. He; P. Mohan; DL. Bhatt; S. Goodman; FW. Verheugt; M. Flather; K. Huber, Apixaban with antiplatelet therapy after acute coronary syndrome., in N Engl J Med, vol. 365, n. 8, agosto 2011, pp. 699-708, DOI:10.1056/NEJMoa1105819, PMID 21780946.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical Cost Reductions Associated with the Usage of Novel Oral Anticoagulants vs. Warfarin Among Atrial Fibrillation Patients, Based on the RE-LY, ROCKET-AF and ARISTOTLE Trials., in J Med Econ, marzo 2012, DOI:10.3111/13696998.2012.680555, PMID 22449118.

oadoi.org

SJ. Connolly, J. Eikelboom; C. Joyner; HC. Diener; R. Hart; S. Golitsyn; G. Flaker; A. Avezum; SH. Hohnloser; R. Diaz; M. Talajic, Apixaban in patients with atrial fibrillation., in N Engl J Med, vol. 364, n. 9, marzo 2011, pp. 806-17, DOI:10.1056/NEJMoa1007432, PMID 21309657.
MR. Lassen, BL. Davidson; A. Gallus; G. Pineo; J. Ansell; D. Deitchman, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement., in J Thromb Haemost, vol. 5, n. 12, dicembre 2007, pp. 2368-75, DOI:10.1111/j.1538-7836.2007.02764.x, PMID 17868430.
MR. Lassen, A. Gallus; GE. Raskob; G. Pineo; D. Chen; LM. Ramirez; MR. Lassen; A. Gallus; G. Pineo; G. Raskob; J. Ansell, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement., in N Engl J Med, vol. 363, n. 26, dicembre 2010, pp. 2487-98, DOI:10.1056/NEJMoa1006885, PMID 21175312.
JH. Alexander, RD. Lopes; S. James; R. Kilaru; Y. He; P. Mohan; DL. Bhatt; S. Goodman; FW. Verheugt; M. Flather; K. Huber, Apixaban with antiplatelet therapy after acute coronary syndrome., in N Engl J Med, vol. 365, n. 8, agosto 2011, pp. 699-708, DOI:10.1056/NEJMoa1105819, PMID 21780946.
Christopher B. Granger, John H. Alexander, John J.V. McMurray, Renato D. Lopes, Elaine M. Hylek, Michael Hanna, Apixaban versus Warfarin in Patients with Atrial Fibrillation, in New England Journal of Medicine, vol. 365, n. 11, 2011, pp. 981–992, DOI:10.1056/NEJMoa1107039. URL consultato il 27 gennaio 2013.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical Cost Reductions Associated with the Usage of Novel Oral Anticoagulants vs. Warfarin Among Atrial Fibrillation Patients, Based on the RE-LY, ROCKET-AF and ARISTOTLE Trials., in J Med Econ, marzo 2012, DOI:10.3111/13696998.2012.680555, PMID 22449118.

pharmastar.it

PHARMASTAR :: Nice, ok ad apixaban nella fibrillazione atriale non valvolare, su pharmastar.it. URL consultato il 27 gennaio 2013.

theheart.org

Nainggolan L, Apixaban better than European enoxaparin regimen for preventing VTE, su theheart.org, theheart.org by WebMD. URL consultato il 1º aprile 2011.